Biogen
BIIB
1,101 hedge funds and large institutions have $51.4B invested in Biogen in 2018 Q1 according to their latest regulatory filings, with 94 funds opening new positions, 424 increasing their positions, 417 reducing their positions, and 101 closing their positions.
2% more repeat investments, than reductions
Existing positions increased: 424 | Existing positions reduced: 417
0.28% less ownership
Funds ownership: 89.1% → 88.83% (-0.28%)
7% less first-time investments, than exits
New positions opened: 94 | Existing positions closed: 101
2% less funds holding
Funds holding: 1,122 → 1,101 (-21)
7% less funds holding in top 10
Funds holding in top 10: 28 → 26 (-2)
14% less capital invested
Capital invested by funds: $60B → $51.4B (-$8.58B)
34% less call options, than puts
Call options by funds: $695M | Put options by funds: $1.05B
Top Buyers
Top Sellers
BIIB Hedge Fund Activity: Q1 2018 in Review
1,101 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2018, worth a combined $51.4B — down 14% from $60B a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of BIIB and 94 opened new positions — a net loss of 7 holders — while 417 trimmed existing stakes and 424 added.
The largest buyer was Deutsche Bank, adding an estimated $700M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.4B.
- 1,101 institutional investors held Biogen (BIIB) as of Q1 2018, down from 1,122 in Q4 2017.
- Funds reported $51.4B of Biogen stock for Q1 2018, down 14% quarter-over-quarter.
- 94 funds opened new Biogen positions in Q1 2018 and 101 closed out, a net change of -7 holders.
- The largest Biogen buyer in Q1 2018 was Deutsche Bank, an estimated $700M added.
- The largest Biogen seller in Q1 2018 was T. Rowe Price Associates, an estimated $1.4B sold.
Based on aggregated 13F filings for Q1 2018.